Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Seagen Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1998-01-01

Employees: 3.2K

Market Cap: -

Website: http://www.seagen.com

Clinical Trials

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck
HER2 Negative Breast Neoplasms
Cutaneous Squamous Cell Cancer
Exocrine Pancreatic Adenocarcinoma
Uterine Cervical Neoplasms
Carcinoma, Non-Small Cell Lung
Esophageal Squamous Cell Carcinoma
Urinary Bladder Neoplasms
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: sigvotatug vedotin
Drug: pembrolizumab
Drug: cisplatin
Drug: carboplatin

First Posted Date: 2020-05-15

Last Posted Date: 2025-06-26

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 1006

Registration Number: NCT04389632

Locations: 🇺🇸
Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸
Providence Medical Foundation, Fullerton, California, United States

and more 117 locations

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer
Gastric Carcinoma
Gastroesophageal Junction Carcinoma
Classical Hodgkin Lymphoma
Diffuse Large B-cell Lymphoma
Peripheral T-cell Lymphoma
Cutaneous Melanoma
Head and Neck Squamous Cell Carcinoma
Bladder Cancer
Ovarian Cancer

Interventions: Drug: SEA-TGT
Drug: sasanlimab
Drug: brentuximab vedotin

First Posted Date: 2020-02-05

Last Posted Date: 2025-02-10

Lead Sponsor: Seagen Inc.

Target Recruit Count: 133

Registration Number: NCT04254107

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 33 locations

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Phase 1

Recruiting

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions: Drug: SEA-CD70
Drug: azacitidine
Drug: Venetoclax

First Posted Date: 2020-01-14

Last Posted Date: 2025-05-13

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 178

Registration Number: NCT04227847

Locations: 🇺🇸
ONeal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States
🇺🇸
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
🇺🇸
IP Address: City of Hope Investigational Drug Services(IDS), Duarte, California, United States

and more 46 locations

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Conditions: HER2-positive Breast Cancer

First Posted Date: 2020-01-07

Last Posted Date: 2025-06-26

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Registration Number: NCT04220203

A Study of SGN-CD228A in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Cutaneous Melanoma
Pleural Mesothelioma
HER2 Negative Breast Neoplasms
Non-small Cell Lung Cancer
Colorectal Cancer
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: SGN-CD228A

First Posted Date: 2019-08-02

Last Posted Date: 2023-03-23

Lead Sponsor: Seagen Inc.

Target Recruit Count: 88

Registration Number: NCT04042480

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 11 locations

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Phase 2

Terminated

Conditions: Melanoma
Small Cell Lung Cancer
Non-small Cell Lung Cancer, Non-squamous
Prostate Cancer
Non-small Cell Lung Cancer, Squamous
Esophageal Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: ladiratuzumab vedotin
Drug: pembrolizumab

First Posted Date: 2019-07-25

Last Posted Date: 2025-03-10

Lead Sponsor: Seagen Inc.

Target Recruit Count: 205

Registration Number: NCT04032704

Locations: 🇺🇸
Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona, United States
🇺🇸
Adventist Health White Memorial, Los Angeles, California, United States
🇺🇸
Providence Medical Foundation, Santa Rosa, California, United States

and more 63 locations

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Phase 3

Active, not recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: tucatinib
Drug: placebo
Drug: T-DM1

First Posted Date: 2019-06-05

Last Posted Date: 2025-06-08

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 466

Registration Number: NCT03975647

Locations: 🇺🇸
University of South Alabama - Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 269 locations

A Safety Study of SGN-CD47M in Patients With Solid Tumors

Phase 1

Terminated

Conditions: Colorectal Cancer
Non-small Cell Lung Carcinoma
Exocrine Pancreatic Carcinoma
Soft Tissue Sarcoma
Breast Carcinoma
Ovarian Carcinoma
Melanoma
Head and Neck Squamous Cell Carcinoma
Gastric Carcinoma

Interventions: Drug: SGN-CD47M

First Posted Date: 2019-05-21

Last Posted Date: 2020-09-17

Lead Sponsor: Seagen Inc.

Target Recruit Count: 16

Registration Number: NCT03957096

Locations: 🇺🇸
Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸
Tennessee Oncology-Nashvilee/Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 2 locations

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Phase 2

Terminated

Conditions: Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma
Peripheral T Cell Lymphoma

Interventions: Drug: brentuximab vedotin

First Posted Date: 2019-05-13

Last Posted Date: 2023-10-13

Lead Sponsor: Seagen Inc.

Target Recruit Count: 12

Registration Number: NCT03947255

Locations: 🇺🇸
Pacific Cancer Medical Center, Anaheim, California, United States
🇺🇸
SCL Health Good Samaritan Medical Center Cancer Centers of Colorado, Lafayette, Colorado, United States
🇺🇸
Memorial Cancer Institute, Pembroke Pines, Florida, United States

and more 16 locations

A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tucatinib

First Posted Date: 2019-04-16

Last Posted Date: 2019-09-06

Lead Sponsor: Seagen Inc.

Target Recruit Count: 36

Registration Number: NCT03914755

Locations: 🇺🇸
PAREXEL International, Early Phase Clinical Unit - Los Angeles, Glendale, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy